Page 11 - Read Online
P. 11
68 Minimally invasive therapies for hepatocellular carcinoma: narrowing the gaps
Kevin M. Sullivan, Raymond S. Yeung
Hepatoma Res 2018;4:68 http://dx.doi.org/10.20517/2394-5079.2018.95
69 Stemness features in liver cancer
Margherita Correnti, Richell Booijink, Giovanni Di Maira, Chiara Raggi, Fabio Marra
Hepatoma Res 2018;4:69 http://dx.doi.org/10.20517/2394-5079.2018.96
70 Direct-acting antivirals and hepatocellular carcinoma occurrence and recurrence in hepatitis C
virus-related liver cirrhosis: fact or fiction
Alberto Zanetto, Sarah Shalaby, Alberto Ferrarese, Chiara Becchetti, Salvatore Sciarrone, Giacomo
Germani, Marco Senzolo, Martina Gambato, Francesco Paolo Russo, Patrizia Burra
Hepatoma Res 2018;4:70 http://dx.doi.org/10.20517/2394-5079.2018.102
71 Efficacy and safety of generic daclatasvir + sofosbuvir ± ribavirin in treatment of genotype 3
infected hepatitis C patients - a real life experience from Pakistan
Muhammad Umar, Tayyab Saeed Akhter, Junaid Sadiq, Samar Saleem, Shoaib Khokhar
Hepatoma Res 2018;4:71 http://dx.doi.org/10.20517/2394-5079.2018.31
72 Surveillance for hepatocellular carcinoma - current status and advances
Kaina Chen, Pik-Eu Chang, George Boon-Bee Goh, Chee-Kiat Tan
Hepatoma Res 2018;4:72 http://dx.doi.org/10.20517/2394-5079.2018.103
73 Simple screening method for the diagnosis of nonB-nonC hepatocellular carcinoma
Kazuhiro Nouso, Yoshie Furubayashi, Shohei Shiota, Akiko Wakuta,Ayano Oonishi, Kazuya
Kariyama, Yasuto Takeuchi, Nozomu Wada, Hideki Onishi, Takuya Adachi, Atsushi Oyama, Chihiro
Dohi, Tetsuya Yasunaka, Yuki Yasunaka, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Hiroyuki
Okada
Hepatoma Res 2018;4:73 http://dx.doi.org/10.20517/2394-5079.2018.93
74 Direct-acting antivirals and chronic hepatitis C: towards elimination
Ricardo A. Franco, James W. Galbraith, Edgar T. Overton, Michael S. Saag
Hepatoma Res 2018;4:74 http://dx.doi.org/10.20517/2394-5079.2018.94
75 The prediction of microvascular invasion of hepatocellular carcinoma using multiple imaging
modalities
Hideyuki Tamai
Hepatoma Res 2018;4:75 http://dx.doi.org/10.20517/2394-5079.2018.98
